戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ithin 18 hours after the administration of a factor Xa inhibitor.
2          Otamixaban is an intravenous direct factor Xa inhibitor.
3 ng within 18 hours after administration of a factor Xa inhibitor.
4 y potent, selective, and orally bioavailable factor Xa inhibitor.
5 rillation was the most common indication for factor Xa inhibitors.
6  available in the United States for the oral factor Xa inhibitors.
7 gned to reverse the anticoagulant effects of factor Xa inhibitors.
8 atheter ablation in AF patients treated with factor Xa inhibitors.
9 arins, fondaparinux, thrombin inhibitors and factor Xa inhibitors.
10 of human factor Xa developed for reversal of factor Xa inhibitors.
11 n amide that is found in previously reported factor Xa inhibitors.
12 nt a novel class of potent dual thrombin and factor Xa inhibitors.
13 y potent, selective, and orally bioavailable factor Xa inhibitors.
14 nce rate of SAB compared with treatment with factor Xa-inhibitors.
15                                     For each factor Xa inhibitor, a two-part randomized placebo-contr
16 on with anticoagulants (thrombin inhibitors, factor Xa inhibitors) act synergistically in inhibiting
17                            Apixaban, an oral factor Xa inhibitor administered in fixed doses, may sim
18                                              Factor Xa inhibitors and aspirin each reduce thrombotic
19                      A number of oral direct factor Xa inhibitors and oral direct thrombin inhibitors
20 erruption, or discontinuation of direct oral factor Xa inhibitor) and the remaining eight (14%) event
21 se of anticoagulants (vitamin K antagonists, factor Xa inhibitors, and direct thrombin inhibitors) fo
22  intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better contr
23 ET 5 trial (Anticoagulation Using the Direct Factor Xa Inhibitor Apixaban During Atrial Fibrillation
24                      Compared with warfarin, factor Xa inhibitors are associated with a lower risk of
25 ry and SAR of ketopiperazino methylazaindole factor Xa inhibitors are described.
26                                   Two direct factor Xa inhibitors are emerging from phase II trials (
27                                  Oral direct factor Xa inhibitors are potentially well tolerated and
28 s), including direct thrombin inhibitors and factor Xa inhibitors, are emerging options for thrombopr
29                            Is treatment with factor Xa inhibitors associated with better efficacy and
30 r prothrombin complex concentrate to reverse factor Xa inhibitor-associated acute major bleeding, nor
31 that AA may have a role in the management of factor Xa inhibitor-associated ICH, although further hig
32 ompared with usual care for the treatment of factor Xa inhibitor-associated ICH.
33 st andexanet alfa (AA) for the management of factor Xa inhibitor-associated intracranial haemorrhage
34 xtended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of str
35 he carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond
36 Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents f
37      Compared with LMWH, lower doses of oral factor Xa inhibitors can achieve a small absolute risk r
38                                              Factor Xa inhibitors can prevent 4 instances of symptoma
39 onfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events
40 ractions that were not found in the previous factor Xa/inhibitor complexes.
41                                          The factor Xa inhibitor DEGR-chloromethyl ketone and an anti
42 ived data from phase 3 trials of direct oral factor Xa inhibitors done at University Hospital Carl Gu
43                             Whether the oral factor Xa inhibitor edoxaban can be an alternative to wa
44                                     The oral factor Xa inhibitor edoxaban has demonstrated safety and
45 F-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a C
46 a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fib
47 rombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin
48                    Two RCTs addressed direct factor Xa inhibitors (either rivaroxaban or apixaban) fo
49 on, was completely inactive as a thrombin or factor Xa inhibitor even after heparin activation.
50                   Treatment of mice with the factor Xa inhibitor fondaparinux during the last 4 wk of
51 eral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analog) and a direct t
52  considerable interest in the development of factor Xa inhibitors for the intervention in thrombic di
53                                   Testing of factor Xa inhibitors for the prevention of cardiovascula
54  been intense interest in the development of factor Xa inhibitors for the treatment of thrombotic dis
55 s, and efficacy of apixaban, an oral, direct factor Xa inhibitor, for prevention of thromboembolism i
56         Compound 1 was the first non-amidine factor Xa inhibitor from our lab that had measurable pot
57 er in the dabigatran group compared with the factor Xa-inhibitor group (22.8 [95% confidence interval
58 the dabigatran group and 356 patients in the factor Xa-inhibitor group were admitted with SAB.
59 A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective a
60 agulants (nOAC), which includes thrombin and factor Xa inhibitors, has been shown to be effective, bu
61 e intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion.
62 nhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and eff
63                           The use of an oral factor Xa inhibitor in patients stabilised after an acut
64 ctive, reversible, and direct small-molecule factor Xa inhibitor in patients with stable coronary dis
65 omplications during therapy with direct oral factor Xa inhibitors in a case series of women of reprod
66 ivaroxaban, apixaban, and edoxaban, the oral factor Xa inhibitors in the most advanced stages of deve
67  the foundation for further investigation of factor Xa inhibitors in the treatment of patients with c
68 ly lower incidence rate of SAB compared with factor Xa-inhibitors (incidence rate ratio, .76; 95% CI,
69           High, but not lower, doses of oral factor Xa inhibitors increased bleeding compared with LM
70         Highly convergent synthesis of these factor Xa inhibitors is also described.
71                     Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may r
72                            Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of s
73                                   The direct factor Xa inhibitors may offer several promising alterna
74                         Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and pre
75                    Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent is
76  oral anticoagulants, such as factor IIa and factor Xa inhibitors, may provide a novel treatment appr
77  in clinical trials suggest that direct oral factor Xa inhibitors might increase menstrual bleeding i
78                         Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared w
79  alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has n
80 se rivaroxaban (2.5 mg twice-daily), an oral factor Xa inhibitor, plus acetylsalicylic acid reduced m
81 e clinical efficacy of PCCs in patients with factor Xa inhibitor-related ICH are needed.
82 evaluate the safety and efficacy of PCCs for factor Xa inhibitor-related ICH in a large, multicenter
83           Therefore, development of the oral factor Xa inhibitors represents a translational science
84 SAR107375), a novel potent dual thrombin and factor Xa inhibitor resulted from a rational optimizatio
85                           Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembol
86                                          The factor Xa inhibitor rivaroxaban reduced mortality and is
87  (Alox12 or Alox15) or administration of the factor Xa inhibitor rivaroxaban significantly reduced AA
88                                     The oral factor Xa inhibitor rivaroxaban was noninferior to warfa
89  thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new or
90                           Recently, the oral factor Xa inhibitors rivaroxaban and apixaban have enter
91 he effects of the DTI dabigatran, the direct factor Xa-inhibitor rivaroxaban, and of 2-O, 3-O desulfa
92 tran compared with patients treated with the factor Xa-inhibitors rivaroxaban, apixaban, and edoxaban
93 olled trial investigating the effects of the factor-Xa inhibitor rivaroxaban.
94 anticoagulation, the use of low doses of the factor Xa inhibitor, rivaroxaban, has shown benefit.
95 twice daily [BID], 110 mg BID), and the oral Factor Xa inhibitors, rivaroxaban and apixaban.
96 inhibitor, dabigatran etexilate, and the two factor Xa inhibitors, rivaroxaban and apixaban.
97                                 The specific factor Xa inhibitor rTAP, when given in fully anticoagul
98 s incorporated into a previously established factor Xa inhibitor series.
99                            Apixaban, an oral factor Xa inhibitor that can be administered in a simple
100                Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in preventio
101              Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the ri
102                             Rivaroxaban is a factor Xa inhibitor that was recently reviewed by the Fo
103 loped a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl
104  We also look retrospectively at a series of factor Xa inhibitors that show an almost 8000-fold range
105 n a series of potent and orally bioavailable factor Xa inhibitors that ultimately led to the discover
106 of reproductive age treated with direct oral factor Xa inhibitors: the non-interventional Dresden NOA
107 of reproductive age who received direct oral factor Xa inhibitor therapy, of whom 57 had vaginal blee
108  in women of reproductive age on direct oral factor Xa inhibitor therapy.
109               Since the approval of the oral factor Xa inhibitors, there have been concerns regarding
110  pathway inhibitor (TFPI), and the selective factor Xa inhibitor, tick anticoagulant peptide (TAP), a
111 d conformations of (13)C,(15)N,(19)F-labeled factor Xa inhibitors to bovine trypsin.
112         Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazol
113  major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly r
114 f an ongoing effort to prepare orally active factor Xa inhibitors using structure-based drug design t
115 l Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, ph
116                   In the secondary analysis, factor Xa inhibitors were associated with a reduced risk
117                                              Factor Xa inhibitors were associated with a reduction in
118                                              Factor Xa inhibitors were associated with lower rates of
119  dabigatran versus patients treated with the factor Xa-inhibitors were examined by multivariable Cox
120 luded because of the intake of a direct oral factor Xa inhibitor which has a strong impact on prothro
121  highly potent, selective, and orally active factor Xa inhibitor which was chosen for clinical develo
122                            Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninf
123              Studies of antistasin, a potent factor Xa inhibitor with anticoagulant properties, were
124 ther optimize the selectivity profile of our factor Xa inhibitors with a series of ortho- and/or para
125  combined treatment of aspirin or C921-78 (a factor Xa inhibitor) with CT50547 or 2-MeSAMP (a P2Y12 a
126 ts with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurrin
127 gned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an ac
128 her rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 20
129 mbinant tick anticoagulant peptide (rTAP), a factor Xa inhibitor, would reduce the thickness of neoin

 
Page Top